Recent Quotes
My Watchlist
Indicators
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

PepGen Inc. - Common Stock (NQ: PEPG )

4.120 -0.370 (-8.24%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about PepGen Inc. - Common Stock

< Previous 1 2 Next >
PepGen Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
From PepGen Inc.
Via Business Wire
PepGen to Participate in Upcoming Investor Conferences
From PepGen Inc.
Via Business Wire
PepGen Announces Presentations at the 29th Annual Congress of the World Muscle Society
From PepGen Inc.
Via Business Wire
Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher
Capricor Therapeutics Inc. (NASDAQ: CAPR) is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like iomyopathy 
Via MarketBeat
Exposures Product Safety
PepGen Announces Christopher Ashton, PhD, to Retire from its Board of Directors
From PepGen Inc.
Via Business Wire
PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Vice President, Research & Development
From PepGen Inc.
Via Business Wire
PepGen Appoints Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development
From PepGen Inc.
Via Business Wire
PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
PepGen Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
From PepGen Inc.
Via Business Wire
PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
PEPG Investors Have Opportunity to Join PepGen Inc. Securities Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
PepGen Announces Positive Data from Low-Dose Cohort of PGN-EDO51 in Ongoing CONNECT1-EDO51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular Dystrophy
From PepGen Inc.
Via Business Wire
PepGen Appoints Afsaneh Mohebbi, Ph.D., as SVP, Portfolio and Program Management and Dave Borah, CFA, as SVP, Investor Relations and Corporate Communications
From PepGen Inc.
Via Business Wire
PepGen Announces Executive Team Promotions
From PepGen Inc.
Via Business Wire
PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
From PepGen Inc.
Via GlobeNewswire
PepGen to Participate in Upcoming Investor Conferences
From PepGen Inc.
Via GlobeNewswire
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
From PepGen Inc.
Via GlobeNewswire
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
From PepGen Inc.
Via GlobeNewswire
PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
From PepGen Inc.
Via GlobeNewswire
PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1
From PepGen Inc.
Via GlobeNewswire
PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock
From PepGen Inc.
Via GlobeNewswire
PepGen soars on Sarepta Therapeutics’ Duchenne drug phase 2 data
PepGen stock is moving higher on expectations of positive Phase 2 clinical trial results for its Duchenne muscular dystrophy (DMD) gene therapy 
Via MarketBeat
Mary Beth DeLena Joins PepGen as General Counsel and Secretary
From PepGen Inc.
Via GlobeNewswire
PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping
From PepGen Inc.
Via GlobeNewswire
PepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
From PepGen Inc.
Via GlobeNewswire
PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors
From PepGen Inc.
Via GlobeNewswire
PepGen Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
From PepGen Inc.
Via GlobeNewswire
PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
From PepGen Inc.
Via GlobeNewswire
PepGen Announces Upcoming Presentations at the 28th Annual Congress of the World Muscle Society and the World Congress of Neurology
From PepGen Inc.
Via GlobeNewswire
PepGen Inc. Announces Clearance of CTA by Health Canada to Begin the FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 in Patients with Myotonic Dystrophy Type 1
The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to PGN-EDODM1 for the treatment of Myotonic Dystrophy Type 1 (DM1) 
From PepGen Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.